Abstract Purpose: Peptide receptors are frequently overexpressed in human tumors, allowing receptortargeted scintigraphic imaging and therapy with radiolabeled peptide analogues. NeuropeptideY (NPY) receptors are new candidates for these applications, based on their high expression in specific cancers. Because NPY receptors are expressed in selected sarcoma cell lines and because novel treatment options are needed for sarcomas, this study assessed the NPY receptor in primary human sarcomas. Experimental Design: Tumor tissues of 88 cases, including Ewing sarcoma family of tumors (ESFT), synovial sarcomas, osteosarcomas, chondrosarcomas, liposarcomas, angiosarcomas, rhabdomyosarcomas, leiomyosarcomas, and desmoid tumors, were investigated for NPY receptor protein with in vitro receptor autoradiography using 125 I-labeled NPY receptor ligands and for NPY receptor mRNA expression with in situ hybridization. Results: ESFT expressed the NPY receptor subtype Y1 on tumor cells in remarkably high incidence (84%) and density (mean, 5,314 dpm/mg tissue). Likewise, synovial sarcomas expressed Y1on tumor cells in high density (mean, 7,497 dpm/mg; incidence, 40%). The remaining tumors expressed NPY receptor subtypes Y1 or Y2 at lower levels. Moreover, many of the sarcomas showed Y1expression on intratumoral blood vessels. In situ hybridization forY1mRNA confirmed the autoradiography results. Conclusions: NPY receptors are novel molecular markers for human sarcomas. Y1 may inhibit growth of specific sarcomas, as previously shown in an in vivo mouse model of human ESFT. The high Y1 expression on tumor cells of ESFT and synovial sarcomas and on blood vessels in many other sarcomas represents an attractive basis for an in vivo tumor targeting.
I-labeled NPY receptor ligands and for NPY receptor mRNA expression with in situ hybridization. Results: ESFT expressed the NPY receptor subtype Y1 on tumor cells in remarkably high incidence (84%) and density (mean, 5,314 dpm/mg tissue). Likewise, synovial sarcomas expressed Y1on tumor cells in high density (mean, 7,497 dpm/mg; incidence, 40%). The remaining tumors expressed NPY receptor subtypes Y1 or Y2 at lower levels. Moreover, many of the sarcomas showed Y1expression on intratumoral blood vessels. In situ hybridization forY1mRNA confirmed the autoradiography results. Conclusions: NPY receptors are novel molecular markers for human sarcomas. Y1 may inhibit growth of specific sarcomas, as previously shown in an in vivo mouse model of human ESFT. The high Y1 expression on tumor cells of ESFT and synovial sarcomas and on blood vessels in many other sarcomas represents an attractive basis for an in vivo tumor targeting.
Many human cancers express specific peptide receptors on the surface membranes of their tumor cells. If present in sufficient amounts, these tumoral peptide receptors can be targeted in vivo with i.v. injected radiolabeled peptide analogues for diagnostic and radiotherapeutic purposes (1) . The clinically best established example is somatostatin receptor targeting of gut endocrine tumors: Using somatostatin analogues that are coupled with a suitable radioisotope, tumors with a high somatostatin receptor expression can either be imaged scintigraphically with high sensitivity or be subjected to a very effective radiotherapy (2, 3) . Promising new candidates for such an in vivo peptide receptor targeting of tumors are neuropeptide Y (NPY) receptors, based on their high expression in specific cancers, for instance, breast carcinomas (4, 5) .
NPY receptors belong to the G protein -coupled receptor superfamily. Five NPY receptor subtypes have been characterized to date, called Y1, Y2, Y4, Y5, and y6 (6) . In humans, Y1, Y2, Y4, and Y5 are physiologically expressed, whereas only Y1 and Y2 have been identified in tumor tissues thus far (4, 7 -9) . The natural ligands for NPY receptors are three closely related peptides, the neurotransmitter NPY and the gut hormones peptide YY (PYY), and pancreatic polypeptide (PP). Physiologically, these peptides have very diverse functions, they regulate, for instance, eating behavior and digestion (10) .
The aim of the present study was to assess the NPY receptor expression in human sarcomas. These tumors were chosen for several reasons. First, evidence of an NPY receptor expression has been found in specific sarcoma cell lines, namely in Ewing sarcoma family of tumors (ESFT) and osteosarcoma cell lines (11 -16) . But at present, it is not known if primary human ESFT or osteosarcomas express NPY receptors in sufficient amounts to allow an in vivo targeting. It is also unknown if any other sarcomas may express NPY receptors. Second, it is important to identify new therapeutic targets in sarcomas, as sarcomas show only limited response to traditional chemotherapy and, if advanced, are afflicted with a poor prognosis (17, 18) . Up to now, however, no peptide receptor has been found to be highly expressed in sarcomas (19, 20) . The NPY receptor expression in sarcomas was investigated with in vitro receptor autoradiography, a method that identifies and morphologically localizes in tissue the actual clinical target, i.e., the binding site of the receptor protein.
Materials and Methods
Tissues. The NPY receptor expression was studied in fresh-frozen tumor tissue samples obtained from surgical resection specimens. Eighty-eight cases were investigated, including 19 ESFT, 5 synovial sarcomas, 9 osteosarcomas, 6 chondrosarcomas, 4 angiosarcomas, 9 rhabdomyosarcomas, 7 leiomyomas, 10 leiomyosarcomas, 13 liposarcomas, and 6 desmoid tumors. The tested tumors originated either from samples investigated previously for other receptors (19 -21) collected in accordance with the required international ethical guidelines or from samples collected prospectively at the Institute of Pathology, University of Berne, in agreement with the principles of the Helsinki Declaration, including informed consent and approval by the Institutional Review Board.
In vitro NPY receptor autoradiography. The NPY receptor expression in the tumor tissues was assessed on the basis of specific 125 I-PYY binding to NPY receptor protein, as described before (4, (1) (2) (3) (4) (5) (6) (7) , NPY (19) (20) (21) (22) (23) , Ala . Slides were exposed to Kodak films Biomax MR for 7 d. The signals on the films were analyzed under a Zeiss stereomicroscope in correlation with morphology using a corresponding H&E-stained tissue section. The signal density was quantitatively assessed using tissue standards for iodinated compounds (Amersham) and a computerassisted image processing system (Analysis Imaging System; Interfocus). In all experiments, rat cerebral cortex and cell pellets of the ESFT cell line SK-N-MC (American Type Culture Collection No. HTB-10; LGC Promochem) were used as positive control for Y1 expression, and rat hippocampus served as positive control for Y2 expression (14, 23) .
In situ hybridization of Y1 mRNA. In situ hybridization of Y1 receptor mRNA was done on cryostat sections of 25 tumors expressing Y1 binding sites in the receptor autoradiography experiments. The procedure was carried out as reported previously (4) . Oligonucleotide probes complementary to nucleotides 493 to 529 of the human Y1 receptor gene labeled with 32 P to specific activities of 0.9 to 2.0 Â 10 4 Ci/mmol were used. In each case, a hybridization signal was considered specific only if in a parallel tissue section the hybridization of the radiolabeled probe was completely blocked by 20-fold excess of unlabeled probe. Furthermore, in all experiments, Y1-expressing breast carcinomas were used as positive control (4), and Y2-expressing tumors as negative control.
Statistical analysis. The Fisher's exact test was used for comparison of NPY receptor frequencies, and the Student's t test for comparison of NPY receptor densities between different sarcoma types. A P value of <0.05 was considered to be statistically significant.
Image acquisition. Photographs were acquired under a Zeiss stereomicroscope with a Nikon Coolpix 990 camera and processed with the Corel Photopaint software.
Results
NPY receptor binding sites on tumor cells of soft tissue and bone tumors. Using in vitro NPY receptor autoradiography, NPY receptors were found to be variably expressed on the tumor cells of sarcomas, as summarized in the table and shown for the individual cases in Fig. 1 . ESFT showed a strikingly high NPY receptor expression, with a receptor incidence of 84% and receptor density values often above 4,000 dpm/mg tissue, corresponding to high receptor numbers in the tumor tissues. Furthermore, synovial sarcomas were remarkable because the receptor positive cases displayed also very high NPY receptor densities. Regarding NPY receptor subtypes, all ESFT and synovial sarcomas expressed solely Y1, based on the complete displacement of 125 I-PYY binding by Y1-selective ligands. The remaining tumors showed a considerably lower NPY receptor expression on the tumor cells compared with ESFT and synovial sarcomas: The NPY receptor incidences were moderate in osteosarcomas and angiosarcomas (however, statistically not significantly lower than in ESFT: P = 0.068 for osteosarcomas and P = 0.194 for angiosarcomas) and low in the other tumors (statistically significantly lower than in ESFT: P = 0.006 for chondrosarcomas, P = 0.012 for rhabdomyosarcomas, P = 0.002 for leiomyosarcomas, P = 0.001 for liposarcomas, and P = 0.006 for desmoid tumors). The NPY receptor density values ranged between moderate and low (Table 1; Fig. 1A ). The NPY receptor density was statistically significantly lower in osteosarcomas (P = 0.008), rhabdomyosarcomas (P = 0.007), leiomyosarcomas (P = 0.029), liposarcomas (P = 0.029), and desmoids tumors (P = 0.006) than in ESFT. As for the NPY receptor subtype expression, angiomatous and leiomyomatous tumors expressed only Y1, as seen with complete displacement of NPY receptor binding sites in blood vessels of soft tissue and bone tumors. Y1 receptors were also identified in intratumoral small arteries. This observation was particularly often made in liposarcomas, desmoid tumors, and leiomyomas, i.e., in a subset of tumors with low NPY receptor expression on the tumor cells. In tumors with high density receptor expression on tumor cells, such as ESFT, we may consider that not all NPY receptor expressing blood vessels can be identified as they may be masked by the high Y1 levels on the surrounding tumor cells.
Typical examples of the vascular Y1 expression in tumors are given in Fig. 3 . The rhabdomyosarcoma in the left column shows many small arteries expressing Y1 in moderate density. In the leiomyosarcoma in the right column, higher magnification reveals that the Y1 receptors are localized in the smooth muscle layer of the vascular wall.
Receptor (1) (2) (3) (4) (5) (6) (7) , NPY (19) (20) (21) (22) (23) , Ala 31 , Aib 32 , Pro 34 ]-hPP (22) was totally inactive at the tumoral receptors. Figure 4 shows typical examples of displacement curves, namely for a Y1-expressing ESFT, a Y1-expressing synovial sarcoma, and a Y2-expressing liposarcoma. We obtained the same rank orders of potencies of NPY receptor subtype -selective ligands in the control cells and tissues, i.e., in the Y1-expressing SK-N-MC cell line, Y1-expressing rat cortex, and Y2-expressing rat hippocampus (4, 12, 14, 23) . These results provide strong evidence of specific identification of Y1 or Y2 on tumor cells and of Y1 on tumoral blood vessels, and rule out the presence of substantial amounts of Y4 or Y5.
Tumoral Y1 receptor transcripts. The tumoral Y1 expression was further confirmed with in situ hybridization of Y1 mRNA. In most tumors with Y1 binding sites in the autoradiography experiments, Y1 transcripts were detected. In general, the tumors with a high density of Y1 binding sites also exhibited high Y1 mRNA levels, as shown with a representative example in Fig. 5 , whereas the tumors with a low density of Y1 binding sites had little or no Y1 transcripts detectable. No Y1 transcripts were present in tumors with Y2 binding by autoradiography.
Discussion
The present study investigates for the first time the expression of NPY receptors, a recently recognized tumor marker (4, 5) , in a large number of primary human sarcomas. Particular Research.
on April 13, 2017. © 2008 American Association for Cancer clincancerres.aacrjournals.org Downloaded from attention is given to the quantitative expression of receptor binding sites in tumor tissues, which represents an important basis for future investigations directed toward clinical applications. ESFT and synovial sarcomas are found to exhibit a strikingly high Y1 expression on the tumor cells. ESFT express NPY receptors in very high incidence, and both tumor types display impressively high Y1 receptor densities, which belong to the highest NPY receptor densities ever found in neoplasia, paralleling those in breast cancer (Table 1; ref. 4) . In comparison, the remaining investigated sarcomas, including osteosarcomas, chondrosarcomas, angiosarcomas, rhabdomyosarcomas, and leiomyosarcomas, as well as gastrointestinal stromal tumors assessed previously for NPY receptors (24) , show moderate to low expression levels of Y1 and Y2, indicating a high heterogeneity of NPY receptor expression among the various sarcoma types. Interestingly, a prominent vascular Y1 expression is observed in many of the sarcomas, in particular those with a low receptor density on tumor cells, such as liposarcomas, desmoid tumors, and leiomyomas.
Several lines of evidence of specific NPY receptor subtype identification are provided in the study. The rank orders of potencies of NPY receptor subtype-selective ligands obtained in the autoradiographic competition experiments, namely highaffinity binding of Y1-or Y2-selective ligands and low-affinity or no binding of Y4-and Y5-selective ligands to the tumor tissues, provide pharmacologic proof of Y1 and Y2 expression and rule out the presence of substantial amounts of Y4 or Y5. Moreover, the NPY receptor binding studies in original ESFT tissues in the present study yield the same results as those done previously in the ESFT-derived cell line SK-N-MC, namely exclusive Y1 expression (13, 14) . In addition, expression of Y1, the most abundant NPY receptor subtype in this series, is substantiated at the transcription level with in situ hybridization.
In various sarcoma cell lines, NPY receptors were shown to be functional. Intracellular signaling was specifically activated upon NPY binding in ESFT and osteosarcoma cell lines (12, 25, 26) . Moreover, NPY receptor activation was found to inhibit SK-N-MC cell proliferation in vitro by induction of apoptosis (4, 27) . Importantly, this effect could also be reproduced in vivo in SK-N-MC cell -derived tumors xenografted into nude mice in the presence of abundant NPY (27) . Furthermore, NPY was shown to act on the vascular system of ESFT. It significantly stimulated tumoral angiogenesis in an in vivo mouse model of a human ESFT cell line (27) . Conversely, NPY may hypothetically also have an inhibitory effect on sarcoma perfusion. Activation of Y1 receptors expressed on the smooth muscle cells of intratumoral small arteries could result in vasoconstriction, as known from the human skeletal muscle (28) . At present, however, it is unclear to what extent such cell line data may be extrapolated to human tumor biology.
Sarcomas with a high NPY receptor expression are candidates for a potential in vivo NPY receptor targeting analogous to the somatostatin receptor targeting of gut endocrine tumors (2, 3) . Specifically, NPY analogues coupled with a chemotherapeutic agent or a radioisotope could be used for a targeted therapy or scintigraphy of sarcomas. Such NPY analogues are currently being developed by the Beck-Sickinger group, for instance an NPY compound coupled with daunorubicin suitable for therapy or an NPY compound coupled with radioactive technetium for scintigraphic imaging (29, 30) . First-choice tumors for such applications would be ESFT and synovial sarcomas, as these tumors frequently express Y1 in high density on the tumor cells. Indeed, high density of receptors has been considered as one prerequisite for the success of somatostatin receptor targeting, where only tumors with high receptor density levels were showing significant clinical responses (31) . Furthermore, sarcomas with an abundant Y1 expression on tumoral blood vessels may also be candidates for therapeutic applications. In these various tumors, NPY analogues coupled with a radioactive isotope may not only induce radionecrosis of the targeted tumor cells but possibly also of intratumoral small arteries. In the future, even tumors with a lower density of NPY receptors may become an indication for targeted radiotherapy. Indeed, the recent observation that somatostatin receptor antagonists show in vivo a considerably stronger and longer-lasting binding to tumors than receptor agonists (32) , has suggested that somatostatin receptor targeting with antagonists may be expanded to lower receptor density tumors. The same may apply to the NPY receptor system. NPY receptor -targeted therapies of sarcomas could be particularly useful in the setting of sarcoma recurrence, which remains, at present, an important therapeutic problem (17, 18) . NPY receptor -targeted scintigraphy might be helpful for imaging of the primary tumor site and the search for metastases in the preoperative diagnostic work-up and follow-up of patients.
Various molecular targets have been identified in sarcomas, however, often only at low levels. Peptide receptors such as neurotensin, vasoactive intestinal peptide, and somatostatin receptors are also expressed in ESFT and synovial sarcomas but in much smaller amounts than NPY receptors (19, 20) . Likewise, c-kit positivity was reported to be strong in only 29% of ESFT (33) . Furthermore, epidermal growth factor receptor and HER-2/neu were expressed at only low levels in about half of synovial sarcomas (34) . Therefore, NPY receptors may belong to the most promising candidates for an in vivo targeting of ESFT and synovial sarcomas identified to date, due to their high expression levels in these tumors compared with other molecular tumor markers.
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